Therapies
The Science
About us
Investors
News

Hit enter to search or ESC to close

Notice of General Meeting 2019

March 13, 2019 Kerry Rowe

Notice of General Meeting 2019

Post navigation

Prana receives Orphan Designation for PBT434 for treatment of MSA

Prana receives A$3.3 million R&D Tax Incentive

Related Posts

Prana Provides Update on IMAGINE Trial and Extension Trial for Alzheimer’s Disease

November 27, 2013

PBT434 data to be presented at the International Congress of Parkinson’s Disease and Movement Disorders

July 8, 2018

IMAGINE Phase 2 clinical trial Investor Conference call

March 1, 2014

Recent Posts

Chairman’s Address to Shareholders 2019 Annual General Meeting
AGM 2019 Presentation
Alterity AGM Investor Conference Call
Alterity’s lead drug candidate receives positive opinion from European medical agency
Quarterly Cash Flow Report

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Therapies
The Science
About us
Investors
News
Contact us

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065